The Board of Appeal of the EPO has issued two decisions concerning appeal cases T 0123/22 and T 1191/22, which relate to the interpretation of Rule 80 EPC. The fundamental que...
Continue reading
G 2/88 provides legal assessment for novelty of a non-medical use claim. G 2/88 allows acknowledging novelty of a non-medical use claim of an old compound for a particular pur...
Continue reading
European Patent EP 2 825 558 concerns a combination therapy of bevacizumab and paclitaxel for platinum-resistant ovarian cancer. The claim was supported by Phase III AURELIA c...
Continue reading
All articles
Maiwald acted as legal advisor to Royalty Pharma in connection with an innovative funding agreement totaling up to $2 billion with Revolution Medicines. The transaction includes up to $1.25 billion in synthe...
Continue reading
Cyprumed GmbH and Merck & Co., Inc. have entered a Non-Exclusive License and Option Agreement to develop oral formulations of peptides using Cyprumed’s drug delivery technology. MSD gains global non-exclusive rights...
Continue reading
The market analysis by Managing IP and the IP STARS ranking 2024 confirm this: The German market for intellectual property remains dynamic and highly competitive. Especially in the field of patent law, numerous law firms were able to maintain and expand their leading positio...
Continue reading
Maiwald in the press
We congratulate Dr. Anna Closs on passing the German patent attorney examination!
Continue reading
Effective January 1, 2025, Maiwald, one of Germany's leading intellectual property law firms, appointed two new Counsel, Dr. Lukas Delvos and Dr. Jian Sun. Lukas Delvos until ...
Continue reading
Staff News
In their recent feature with Managing IP, senior representatives from Maiwald – Dr. Anja Fux, Dr. Derk Vos, Heike Roeder-Hitschke, Dr. Nils Braun and Martina Boidol...
Continue reading
This article covers the most recent developments regarding the European Research Exemption, which permits the use of patented inventions for research purposes, as well as the ...
Continue reading
The jurisdictional reach of the Unified Patent Court (UPC) was a widely and controversially discussed topic from the outset. Some practitioners took the view that the UPC also...
Continue reading
All publications
We are delighted to have been honoured once again by Managing IP (MIP) as a "Top Tier Firm" in the 2025 IP Stars Patent Ranking. With awards in the categories of "Patent Prose...
Continue reading
We are delighted that our colleague Dr. Marco Stief has once again been recognized as one of the leading practionee...
Continue reading
We are delighted that Maiwald has once again been recognised in four categories in this year's Leaders League Ranking 2025:
Continue reading
All awards
Wed.
21
We are pleased that Dr. Eva Ehlich was an expert at the 18th C5 Communications Forum on “Pharma & Biotech Patent Litigation in Europe” in Amsterdam. Eva gave a presentation on “Plausibility and Post-Publication Evidence in Inventive Step ...
Continue reading
Tue.
20
The Oblon and Maiwald firms were pleased to host a complimentary joint international symposium on:U.S. and European Patent Practice: Important Aspects for Practitioners At the 2025 joint symposium, selected current aspects of protecting innovations in the U.S. and Europe were examined, considering bo...
Continue reading
Sat.
17
The International Trademark Association's (INTA) Annual Meeting took place in San Diego from May 17 to 21 this year. Maiwald was among the many companies and law firms in attendance, represented by Susanna Heurung,
Continue reading
Thu.
15
Patent law news: EPO case law, software and UPC (Lectures will be held in German) On May 15, we had the pleasure of hosting another Maiwald seminar in our office. Thank you to the speakers and everyone involved for making this an interesting afternoon and ensuring the event ran smoothly.
Continue reading
All events